Raza M Alvi1, Matthew J Frigault2, Michael G Fradley3, Michael D Jain4, Syed S Mahmood5, Magid Awadalla1, Dae Hyun Lee3, Daniel A Zlotoff6, Lili Zhang1, Zsofia D Drobni1, Malek Z O Hassan1, Emmanuel Bassily3, Isaac Rhea3, Roohi Ismail-Khan3, Connor P Mulligan1, Dahlia Banerji1, Aleksandr Lazaryan7, Bijal D Shah7, Adam Rokicki1, Noopur Raje8, Julio C Chavez7, Jeremy Abramson8, Frederick L Locke4, Tomas G Neilan9. 1. Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 2. Cellular Immunotherapy Program, Division of Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 3. Cardio-Oncology Program, Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine and Moffitt Cancer Center, Tampa, Florida. 4. Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida. 5. Division of Cardiology, New York-Presbyterian Hospital, Weil Cornell Medical Center, New York, New York. 6. Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 7. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida. 8. Division of Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 9. Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: tneilan@mgh.harvard.edu.
Abstract
BACKGROUND: Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells. There are limited data characterizing cardiac toxicity and cardiovascular (CV) events among adults treated with CAR-T. OBJECTIVES: The purpose of this study was to evaluate the possible cardiac toxicities of CAR-T. METHODS: The registry included 137 patients who received CAR-T. Covariates included the occurrence and grade of cytokine release syndrome (CRS) and the administration of tocilizumab for CRS. Cardiac toxicity was defined as a decrease in the left ventricular ejection fraction or an increase in serum troponin. Cardiovascular events were a composite of arrhythmias, decompensated heart failure, and CV death. RESULTS: The median age was 62 years (interquartile range [IQR]: 54 to 70 years), 67% were male, 88% had lymphoma, and 8% had myeloma. Approximately 50% were treated with commercial CAR-T (Yescarta or Kymriah), and the remainder received noncommercial products. CRS, occurring a median of 5 days (IQR: 2 to 7 days) after CAR-T, occurred in 59%, and 39% were grade ≥2. Tocilizumab was administered to 56 patients (41%) with CRS, at a median of 27 h (IQR: 16 to 48 h) after onset. An elevated troponin occurred in 29 of 53 tested patients (54%), and a decreased left ventricular ejection fraction in 8 of 29 (28%); each occurred only in patients with grade ≥2 CRS. There were 17 CV events (12%, 6 CV deaths, 6 decompensated heart failure, and 5 arrhythmias; median time to event of 21 days), all occurred with grade ≥2 CRS (31% patients with grade ≥2 CRS), and 95% of events occurred after an elevated troponin. The duration between CRS onset and tocilizumab administration was associated with CV events, where the risk increased 1.7-fold with each 12-h delay to tocilizumab. CONCLUSIONS: Among adults, cardiac injury and CV events are common post-CAR-T. There was a graded relationship among CRS, elevated troponin, and CV events, and a shorter time from CRS onset to tocilizumab was associated with a lower rate of CV events.
BACKGROUND: Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells. There are limited data characterizing cardiac toxicity and cardiovascular (CV) events among adults treated with CAR-T. OBJECTIVES: The purpose of this study was to evaluate the possible cardiac toxicities of CAR-T. METHODS: The registry included 137 patients who received CAR-T. Covariates included the occurrence and grade of cytokine release syndrome (CRS) and the administration of tocilizumab for CRS. Cardiac toxicity was defined as a decrease in the left ventricular ejection fraction or an increase in serum troponin. Cardiovascular events were a composite of arrhythmias, decompensated heart failure, and CV death. RESULTS: The median age was 62 years (interquartile range [IQR]: 54 to 70 years), 67% were male, 88% had lymphoma, and 8% had myeloma. Approximately 50% were treated with commercial CAR-T (Yescarta or Kymriah), and the remainder received noncommercial products. CRS, occurring a median of 5 days (IQR: 2 to 7 days) after CAR-T, occurred in 59%, and 39% were grade ≥2. Tocilizumab was administered to 56 patients (41%) with CRS, at a median of 27 h (IQR: 16 to 48 h) after onset. An elevated troponin occurred in 29 of 53 tested patients (54%), and a decreased left ventricular ejection fraction in 8 of 29 (28%); each occurred only in patients with grade ≥2 CRS. There were 17 CV events (12%, 6 CV deaths, 6 decompensated heart failure, and 5 arrhythmias; median time to event of 21 days), all occurred with grade ≥2 CRS (31% patients with grade ≥2 CRS), and 95% of events occurred after an elevated troponin. The duration between CRS onset and tocilizumab administration was associated with CV events, where the risk increased 1.7-fold with each 12-h delay to tocilizumab. CONCLUSIONS: Among adults, cardiac injury and CV events are common post-CAR-T. There was a graded relationship among CRS, elevated troponin, and CV events, and a shorter time from CRS onset to tocilizumab was associated with a lower rate of CV events.
Authors: Jose A Alvarez-Cardona; Jordan Ray; Joseph Carver; Vlad Zaha; Richard Cheng; Eric Yang; Joshua D Mitchell; Keith Stockerl-Goldstein; Lavanya Kondapalli; Susan Dent; Anita Arnold; Sherry Ann Brown; Monica Leja; Ana Barac; Daniel J Lenihan; Joerg Herrmann Journal: J Am Coll Cardiol Date: 2020-11-10 Impact factor: 24.094
Authors: Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann Journal: CA Cancer J Clin Date: 2020-09-10 Impact factor: 508.702
Authors: Rawan Faramand; Michael Jain; Verena Staedtke; Hiroshi Kotani; Renyuan Bai; Kayla Reid; Sae Bom Lee; Kristen Spitler; Xuefeng Wang; Biwei Cao; Javier Pinilla; Aleksander Lazaryan; Farhad Khimani; Bijal Shah; Julio C Chavez; Taiga Nishihori; Asmita Mishra; John Mullinax; Ricardo Gonzalez; Mohammad Hussaini; Marian Dam; Brigett D Brandjes; Christina A Bachmeier; Claudio Anasetti; Frederick L Locke; Marco L Davila Journal: Clin Cancer Res Date: 2020-07-15 Impact factor: 12.531
Authors: Gabriel E Molina; Leyre Zubiri; Justine V Cohen; Sienna M Durbin; Laura Petrillo; Ian M Allen; Yonina R Murciano-Goroff; Michael Dougan; Molly F Thomas; Alexander T Faje; Michelle Rengarajan; Amanda C Guidon; Steven T Chen; Daniel Okin; Benjamin D Medoff; Mazen Nasrallah; Minna J Kohler; Sara R Schoenfeld; Rebecca S Karp Leaf; Meghan E Sise; Tomas G Neilan; Daniel A Zlotoff; Jocelyn R Farmer; Meghan J Mooradian; Aditya Bardia; Minh Mai; Ryan J Sullivan; Yevgeniy R Semenov; Alexandra Chloé Villani; Kerry L Reynolds Journal: Oncologist Date: 2021-03-31
Authors: Virginia S Hahn; Kathleen W Zhang; Lova Sun; Vivek Narayan; Daniel J Lenihan; Bonnie Ky Journal: Circ Res Date: 2021-05-13 Impact factor: 17.367
Authors: Michael G Fradley; Theresa M Beckie; Sherry Ann Brown; Richard K Cheng; Susan F Dent; Anju Nohria; Kristen K Patton; Jagmeet P Singh; Brian Olshansky Journal: Circulation Date: 2021-06-17 Impact factor: 29.690